Skye Bioscience (SKYE) Receivables (2012 - 2022)

Skye Bioscience (SKYE) posted quarterly Receivables of $50000.0 for Q3 2022, up 41.14% quarter-over-quarter from $35425.0 in Q2 2014.

Skye Bioscience (SKYE) Receivables (2012 - 2022) Analysis & Trends

Skye Bioscience (SKYE) has reported Receivables for 4 consecutive years, with $50000.0 the latest figure, recorded in Q3 2022.

In Q3 2022, Receivables changed N/A year-over-year to $50000.0; the TTM figure through Sep 2022 stood at $50000.0 (changed N/A YoY), while the FY2013 annual figure was $25338.0, up 266.9% from the prior year.
Receivables climbed to $50000.0 in Q3 2022 per SKYE's latest filing, from $35425.0 in the prior quarter.
Across five years, Receivables topped out at $50000.0 in Q3 2022 and bottomed at $50000.0 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.81 Bn	131.96 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	86.56 Bn	78.56 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	65.72 Bn	60.53 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.75 Bn	53.61 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.59 Bn	10.19 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.63 Bn	26.47 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.24 Bn	26.40 Bn	-	-
10	Skye Bioscience	10.68 Mn	10.68 Mn	-	-

Download Data